Delayed enhancement magnetic resonance imaging in nonischemic myocardial disease

Journal of Thoracic Imaging

Volumn 28, Issue 2, 2013, Pages 84-95

  Moraes, Gustavo L ^a   Higgins, Charles B ^b   Ordovas, Karen G ^c  

^a HOSPITAL MÃE DE DEUS   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Delayed enhancement; Magnetic resonance imaging; Nonischemic myocardial disease

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM CHELATE;

ANGIOCARDIOGRAPHY; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CHURG STRAUSS SYNDROME; CONGESTIVE CARDIOMYOPATHY; CONVENTIONAL ANGIOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FABRY DISEASE; HEART AMYLOIDOSIS; HEART DEATH; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE DYSPLASIA; HISTOPATHOLOGY; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ENHANCEMENT; IMAGE QUALITY; ISCHEMIC HEART DISEASE; MYOCARDITIS; NONISCHEMIC CARDIOMYOPATHY; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RELAXATION TIME; REVIEW; SARCOIDOSIS; SIGNAL NOISE RATIO; SYSTEMIC SCLEROSIS;

AMYLOIDOSIS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; DIAGNOSIS, DIFFERENTIAL; GADOLINIUM; HEART DISEASES; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MYOCARDIAL ISCHEMIA; MYOCARDITIS; PROGNOSIS; SCLEROSIS;

EID: 84874644548     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0b013e3182828f89     Document Type: Review

References (51)

1. Arheden H, Saeed M, Higgins CB, et al. Measurement of the distribution volume of gadopentetate dimeglumine at echo-planar MR imaging to quantify myocardial infarction: comparison with 99mTc-DTPA autoradiography in rats. Radiology. 1999;211:698-708.
2. Kim RJ, Chen EL, Lima JA, et al. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318-3326.
3. Ordovas KG, Higgins CB. Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology. 2011;261:358-374.
4. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215-223.
5. Kellman P, Arai AE, McVeigh ER, et al. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med. 2002;47:372-383.
6. Wagner A, Mahrholdt H, Thomson L, et al. Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol. 2006;47:2027-2033.
7. Schmidt A, Azevedo CF, Cheng A, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007;115:2006-2014.
8. Yan AT, Shayne AJ, Brown KA, et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32-39.
9. Cummings KW, Bhalla S, Javidan-Nejad C, et al. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics. 2009;29:89-103.
10. de Roos A, van Rossum AC, van der Wall E, et al. Reperfused and nonreperfused myocardial infarction: diagnostic potential of Gd-DTPA-enhanced MR imaging. Radiology. 1989;172:717-720.
11. Ordovas KG, Reddy GP, Higgins CB. MRI in nonischemic acquired heart disease. J Magn Reson Imaging. 2008;27:1195-1213.
12. Angelini A, Calzolari V, Calabrese F, et al. Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis. Heart. 2000;84:245-250.
13. Laissy JP, Hyafil F, Feldman LJ, et al. Differentiating acute myocardial infarction from myocarditis: diagnostic value of early-and delayed-perfusion cardiac MR imaging. Radiology. 2005;237:75-82.
14. Dickerson JA, Raman SV, Baker PM, et al. Relationship of cardiac magnetic resonance imaging and myocardial biopsy in the evaluation of nonischemic cardiomyopathy. Congest Heart Fail. 2012. [Epub ahead of print].
15. Lurz P, Eitel I, Adam J, et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging. 2012;5:513-524.
16. Grun S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59:1604-1615.
17. De Cobelli F, Pieroni M, Esposito A, et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol. 2006;47:1649-1654.
18. De Smet K, Verdries D, Tanaka K, et al. MRI in the assessment of non ischemic myocardial diseases. Eur J Radiol. 2012;81:1546-1548.
19. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54-59.
20. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardio-myopathy. J Am Coll Cardiol. 2006;48:1977-1985.
21. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260-2264.
22. Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:1333-1340.
23. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40: 2156-2164.
24. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369-1374.
25. Satoh H, Matoh F, Shiraki K, et al. Delayed enhancement on cardiac magnetic resonance and clinical, morphological, and electrocardiographical features in hypertrophic cardiomyop-athy. J Card Fail. 2009;15:419-427.
26. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875-887.
27. Green JJ, Berger JS, Kramer CM, et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:370-377.
28. Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561-1567.
29. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97:75-84.
30. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-193.
31. Selvanayagam JB, Leong DP. MR imaging and cardiac amyloidosis where to go from here? JACC Cardiovasc Imaging. 2010;3:165-167.
32. Sanz J. Evolving diagnostic and prognostic imaging of the various cardiomyopathies. Ann N Y Acad Sci. 2012;1254:123-130.
33. Shammas RL, Movahed A. Sarcoidosis of the heart. Clin Cardiol. 1993;16:462-472.
34. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204-1211.
35. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86-108.
36. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-1977.
37. Ichinose A, Otani H, Oikawa M, et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. Am J Roentgenol. 2008;191:862-869.
38. Matoh F, Satoh H, Shiraki K, et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol. 2008;51:179-188.
39. Gupta A, Singh Gulati G, Seth S, et al. Cardiac MRI in restrictive cardiomyopathy. Clin Radiol. 2012;67:95-105.
40. Basso C, Thiene G, Corrado D, et al. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation. 1996;94:983-991.
41. Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115:1710-1720.
42. Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45:98-103.
43. Pfluger HB, Phrommintikul A, Mariani JA, et al. Utility of myocardial fibrosis and fatty infiltration detected by cardiac magnetic resonance imaging in the diagnosis of arrhythmo-genic right ventricular dysplasia-a single centre experience. Heart Lung Circ. 2008;17:478-483.
44. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31:806-814.
45. Bulkley BH, Ridolfi RL, Salyer WR, et al. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation. 1976;53:483-490.
46. Tzelepis GE, Kelekis NL, Plastiras SC, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum. 2007;56:3827-3836.
47. Kobayashi H, Yokoe I, Hirano M, et al. Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol. 2009;36:106-112.
48. Baccouche H, Yilmaz A, Alscher D, et al. Images in cardiovascular medicine. Magnetic resonance assessment and therapy monitoring of cardiac involvement in Churg-Strauss syndrome. Circulation. 2008;117:1745-1749.
49. Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum. 2010;62:627-634.
50. Lelovas P, Dontas I, Bassiakou E, et al. Cardiac implications of Lyme disease, diagnosis and therapeutic approach. Int J Cardiol. 2008;129:15-21.
51. Naik M, Kim D, O'Brien F, et al. Images in cardiovascular medicine. Lyme carditis. Circulation. 2008;118:1881-1884.